COMPASS Pathways成功达成第二项三期临床试验主要终点,评估Comp360裸盖菇素治疗难治性抑郁症疗效

美股速递
Feb 17

COMPASS Pathways plc(股票代码:CMPS)近日宣布,其针对难治性抑郁症治疗的创新疗法Comp360裸盖菇素,在第二项关键的三期临床试验中成功达到主要研究终点。这一突破性进展标志着该疗法在验证其安全性与有效性方面迈出了坚实一步,为全球数百万受难治性抑郁症困扰的患者带来了新的希望。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10